Trial Profile

Phase I Study of AVID200 in Patients With Myelofibrosis (Myeloproliferative Neoplasms Research Consortium [MPN-RC] 118)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BMS-986416 (Primary)
Indications Myelofibrosis
Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

06 Jul 2022 Status changed from active, no longer recruiting to completed.
14 Dec 2021 Updated safety and efficacy results of the phase 1b dose expansion stage at the two highest doses tested (70 mg (B) and 180 mg (B) presented at the 63rd American Society of Hematology Annual Meeting and Exposition
19 May 2021 Planned primary completion date changed from 1 Mar 2021 to 1 Aug 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com